Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes
Ahmet Dogan Ergin
1, 2, 3
,
Burcu Üner
4
,
Şencan BALCI
2
,
Çağlar Demirbağ
5
,
Camillo Benetti
6
,
Çağatay OLTULU
7
4
Department of Pharmaceutical Technology, Faculty of Pharmacy, St. Louis College of Pharmacy, United States of America
|
Publication type: Journal Article
Publication date: 2023-11-01
scimago Q1
wos Q2
SJR: 0.737
CiteScore: 7.2
Impact factor: 3.8
ISSN: 00223549, 15206017
PubMed ID:
37506768
Pharmaceutical Science
Abstract
Coenzyme Q10 (CoQ10) is a fat-soluble vitamin-with a benzoquinone-like structure. CoQ10 plays a role in membrane stability, energy conversion, and ATP production. It is also one of the important antioxidants in the body. The bioavailability of exogenous CoQ10 is extremely low due to its poor aqueous solubility and large molecular mass. In this study, mixed proniosomal drug delivery systems have been used to increase solubility and bioavailability of CoQ10. Arginine (semi-essential amino acid) was incorporated in the formulation composition to achieve higher efficacy by boosting nitric oxide presence, endothelial dysfunction, and cellular uptake. Proniosomes were investigated in terms of particle size, polydispersity index, zeta potential, encapsulation efficiency, and process yield, and optimization studies were carried on by utilizing STATISTICA 8.0 software considering dependent factors (carrier amount, drug amount, and surfactant ratio). Optimum proniosome formulation (particle size 187.5 ± 16.35 nm, zeta potential: -44.7 ± 12.8 mV, encapsulation efficiency 99.05±0.30%, and product yield: 90.55%) was evaluated for thermal analysis, in-vitro drug release using microcentrifuge method. In-vitro cytotoxicity studies of proniosomes were performed on intestinal Epithelial Cells (Cellartis®, ChiPSC18) and no cytotoxic effects was seen during the 72 h. Besides, anti Alzheimer effect was investigated on APPSL-GFP lentivirus-infected human neural cells (APPSL-GFP-l-HNC) and Alzheimer biomarkers (p-tau181 and p-tau217). While CoQ10’s relative bioavailability was statistically increased by proniosome compared to CoQ10 suspension (p<0.01, Grubb test). PK parameters of proniosome formulation, obtained with non-compartmental modeling, were fitting to the data (R2=0.956±0.026). The study results proved that proniosomal formulation has a high potential drug delivery system for both increasing bioavailability and anti-Alzheimer effect of CoQ10.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
|
|
|
Journal of Drug Delivery Science and Technology
2 publications, 28.57%
|
|
|
Molecules
1 publication, 14.29%
|
|
|
All Life
1 publication, 14.29%
|
|
|
BioNanoScience
1 publication, 14.29%
|
|
|
ACS Applied Bio Materials
1 publication, 14.29%
|
|
|
Antioxidants
1 publication, 14.29%
|
|
|
1
2
|
Publishers
|
1
2
|
|
|
MDPI
2 publications, 28.57%
|
|
|
Elsevier
2 publications, 28.57%
|
|
|
Taylor & Francis
1 publication, 14.29%
|
|
|
Springer Nature
1 publication, 14.29%
|
|
|
American Chemical Society (ACS)
1 publication, 14.29%
|
|
|
1
2
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
7
Total citations:
7
Citations from 2024:
6
(85.71%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Ergin A. D. et al. Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes // Journal of Pharmaceutical Sciences. 2023. Vol. 112. No. 11. pp. 2921-2932.
GOST all authors (up to 50)
Copy
Ergin A. D., Üner B., BALCI Ş., Demirbağ Ç., Benetti C., OLTULU Ç. Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes // Journal of Pharmaceutical Sciences. 2023. Vol. 112. No. 11. pp. 2921-2932.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.xphs.2023.07.020
UR - https://doi.org/10.1016/j.xphs.2023.07.020
TI - Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes
T2 - Journal of Pharmaceutical Sciences
AU - Ergin, Ahmet Dogan
AU - Üner, Burcu
AU - BALCI, Şencan
AU - Demirbağ, Çağlar
AU - Benetti, Camillo
AU - OLTULU, Çağatay
PY - 2023
DA - 2023/11/01
PB - Elsevier
SP - 2921-2932
IS - 11
VL - 112
PMID - 37506768
SN - 0022-3549
SN - 1520-6017
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2023_Ergin,
author = {Ahmet Dogan Ergin and Burcu Üner and Şencan BALCI and Çağlar Demirbağ and Camillo Benetti and Çağatay OLTULU},
title = {Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes},
journal = {Journal of Pharmaceutical Sciences},
year = {2023},
volume = {112},
publisher = {Elsevier},
month = {nov},
url = {https://doi.org/10.1016/j.xphs.2023.07.020},
number = {11},
pages = {2921--2932},
doi = {10.1016/j.xphs.2023.07.020}
}
Cite this
MLA
Copy
Ergin, Ahmet Dogan, et al. “Improving the bioavailability and efficacy of coenzyme q10 on Alzheimer's disease through the arginine based proniosomes.” Journal of Pharmaceutical Sciences, vol. 112, no. 11, Nov. 2023, pp. 2921-2932. https://doi.org/10.1016/j.xphs.2023.07.020.